



1 December 2023

ASX Announcement

Island Pharmaceuticals appoints new Joint Company Secretaries

MELBOURNE Australia, 1 December 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to announce that today Cameron Jones and Stephanie Vipond of Bio101 Financial Advisory ("Bio101") have been appointed as Joint Company Secretaries of the Company.

The appointment will complement Cameron's role of Chief Financial Officer of the Company, which he has held since IPO. Cameron is the Managing Director of Bio101, a financial services firm providing accounting, tax and company secretarial services specialising in healthcare and life science sectors.

Stephanie is an experienced Company Secretary from Bio101, providing company secretarial services to a number of ASX listed and unlisted entities in the healthcare sector. Stephanie holds a Bachelor of Commerce and Law and a Certificate in Governance Practice.

The appointment follows the resignation of Mr Peter Webse as Company Secretary, effective 1 December 2023. The Board would like to thank Peter for his service since his appointment to the role of Company Secretary in July 2020 including throughout the IPO process.

Mr Jones and Ms Vipond are responsible for communications with ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com



Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.